Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Providers Offer Varying Approaches To Tracking, Using Discounts At Hearing

Executive Summary

House Energy and Commerce Committee Chair Greg Walden, R-Ore., expresses frustration at lack of reliable data on the way providers account for 340B drug discounts at Oct. 11 hearing.

You may also be interested in...



340B Provider Reforms Gaining Momentum In Congress

House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.

Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?

PhRMA is stepping up its advocacy for 340B reform, noting recent reduction in Medicare payments for 340B is encouraging in that it indicates Administration may be open to further change.

340B Reforms: Oversight Hearing Suggests Slow, Piecemeal Approach

There appears to be bipartisan interest in beefing up HRSA’s ability to oversee the 340B program – but the next step is likely to be more hearings and fact-finding, not immediate legislative changes.

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel